Notable companies
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Intra-Cellular Therapies (NASDAQ:ITCI).
Industry description
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index.
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
Market Cap
The average market capitalization across the SPDR® S&P Pharmaceuticals ETF ETF is 127.87B. The market cap for tickers in the group ranges from 4.35B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PRGO at 4.35B.
High and low price notable news
The average weekly price growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was 5%. For the same ETF, the average monthly price growth was 17%, and the average quarterly price growth was 26%. AXSM experienced the highest price growth at 5%, while JAZZ experienced the biggest fall at -6%.
Volume
The average weekly volume growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was 39%. For the same stocks of the ETF, the average monthly volume growth was -18% and the average quarterly volume growth was -32%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 48
P/E Growth Rating: 60
Price Growth Rating: 45
SMR Rating: 69
Profit Risk Rating: 57
Seasonality Score: -34 (-100 ... +100)